Interview with Devaney Baccarin, VP & General Manager, Astellas Pharma…
In July 2011, Astellas celebrated its two-year anniversary in Brazil. However, we saw entry into Russia in 1992, China in 1994, and India in 2008. What was it about Brazil…
Address: Avenida das Nações Unidas, 14.171, Rochaverá Corporate Towers, Torre Marble – 3º andar, Cj. 302,Brazil
Tel: (55 11) 3027-4500
Web: http://www.astellasfarma.com.br/
In July 2009, Astellas Pharma Brazil (AFB) was created due to remarkable growth of the economy in the sector of health care. In April 2010, the Brazilian subsidiary started to promote and distribute products directly that were licensed to other companies.
In Brazil, specifically, Astellas is focused on three areas encompassed in the Astellas Group, Dermatology, Urology and Infectious Diseases. These are the foundations for growth and recognition of Astellas in the Brazilian pharmaceutical market.
Astellas Brazil focuses on becoming the leader in the Brazilian pharmaceutical industry, supports the company’s business philosophy, a VISION 2015, which seeks to become a ‘world leader in the category.’
Omnic®, Omnic OCAS®, Vesicare, Mycamine
In July 2011, Astellas celebrated its two-year anniversary in Brazil. However, we saw entry into Russia in 1992, China in 1994, and India in 2008. What was it about Brazil…
In the past four years, Brazil’s pharmaceutical market has more than doubled. To what do you attribute this astounding growth? In Brazil there is a strong income inequality. As the…
Sao Paulo state is responsible for some 85% of pharmaceutical production, and last week Minister Pimentel was in the city of Sao Paulo elaborating on his BrazilMaior plan with strategic…
Besins finally arrived in Brazil in 2010. In addition to introducing the company to the market, would you also elaborate on the strategic motivation behind this decision? Besins Healthcare is…
Much has changed at Bomi since we last met in 2007. At that time, you were launching your new facilities, with 72,000 square metres of built area, 14 metres free…
When we met Servier Brazil five years ago the company had major ambitions: ‘grow more than 10% for the five following years’. How have these expectations turned out to be?…
Mr. Mauricio, you’ve mentioned that Brazil is a different kind of market for Octapharma, one strongly based on price, and that because of this it’s hard to add value. Could…
When we were in Australia, we met with the “star scientist” Ian Frazier, who was Australian of the Year in 2009 for his co-discovery of Merck’s Gardasil. Or Singulair, which…
In an exclusive interview, Otto Philipp Braun, part of medtech giant B. Braun’s family dynasty, discusses his achievements as MD in Brazil, the company’s operations in the country and globally, as…
When we met you in 2007, as the head of the former Igefarma, the company was undergoing a transition – from branded generics into dermocosmetics and women’s health. But since…
Rogerio, you were one of the people responsible for integrating two well-established companies in the Brazilian market with the acquisition of Exel by DHL in late 2005. How challenging was…
You have 25 years of experience in the Brazilian pharmaceutical industry, witnessing the major transformations of this market and the fast emergence of generics. Regarding your background and experience at…
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
See our Cookie Privacy Policy Here
